Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC
- 760 Downloads
Dendritic cells (DCs) could be used as potential cellular adjuvant for the production of specific tumor vaccines.
Our study was aimed to evaluate the safety and efficacy of autologous pulsed DC vaccine in advanced hepatocellular carcinoma (HCC) patients in comparison with supportive treatment.
Thirty patients with advanced HCC not suitable for radical or loco-regional therapies were enrolled. Patients were divided into 2 groups, group I consisted of 15 patients received I.D vaccination with mature autologous DCs pulsed ex vivo with a liver tumor cell line lysate. Group II (control group, no. 15) received supportive treatment. One hundred and 4 ml of venous blood were obtained from each patient to generate DCs. DCs were identified by CD80, CD83, CD86 and HLA-DR expressions using flow cytometry. Follow up at 3, and 6 months post injection by clinical, radiological and laboratory assessment was done.
Improvement in overall survival was observed. Partial radiological response was obtained in 2 patients (13.3 %), stable course in 9 patients (60 %) and 4 patients (26.7 %) showed progressive disease (died at 4 months post-injection). Both CD8+ T cells and serum interferon gamma were elevated after DCs injection.
Autologous DC vaccination in advanced HCC patients is safe and well tolerate.
KeywordsDCs HCC Adjuvant immunotherapy
Alfa feto protein
This study was supported in part by grants from Kasr Al-Aini Hospital. We also thank El-Ansary private laboratories and our patients for their willing participation in our research.
Conflict of interest
The authors declare no conflicts of interest.
- Gonzalez-Carmona MA, Marten A, Hoffmann P et al (2006) Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int 26:369–379PubMedCrossRefGoogle Scholar